論文発表報告

原著論文

[Last reviewed: 14 July , 2023]

  1. Terutsugu Koya , Kenichi Yoshida , Misa Togi , Yo Niida , Sumihito Togi , Hiroki Ura , Shuichi Mizuta ,Tomohisa Kato, Jr. , Sohsuke Yamada , Takeo Shibata , Yi-Chang Liu , Shyng-Shiou Yuan ,Deng-Chyang Wu , Hirohito Kobayashi , Taiju Utsugisawa , Hitoshi Kanno  and Shigetaka Shimodaira　Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells. Cancers 2023, 15, 3627.https://doi.org/10.3390/cancers15143627
  2. Terutsugu Koya , Yo Niida , Misa Togi , Kenichi Yoshida , Takuya Sakamoto , Hiroki Ura , Sumihito Togi , Tomohisa Kato Jr , Sohsuke Yamada , Haruo Sugiyama , Shigeo Koido , Shigetaka Shimodaira The Detection of Immunity against WT1 and SMAD4P130L of EpCAM+ Cancer Cells in Malignant Pleural Effusion Int J Mol Sci. 2022 Oct; 23(20): 12177. doi: 10.3390/ijms232012177.
  3. Fuku A, Taki Y, Nakamura Y, Kitajima H, Takaki T, Koya T, Tanida I, Nozaki K, Sunami H, Hirata H, Tachi Y, Masauji T, Yamamoto N, Ishigaki Y, Shimodaira S, Shimizu Y, Ichiseki T, Kaneuji A, Osawa S, Kawahara N. Evaluation of the Usefulness of Human Adipose-Derived Stem Cell Spheroids Formed Using SphereRing® and the Lethal Damage Sensitivity to Synovial Fluid In Vitro. Cells. 2022 Jan 20;11(3):337. doi: 10.3390/cells11030337.
  4. Kawaguchi H, Sakamoto T, Koya T, Togi M, Date I, Watanabe A, Yoshida K, Kato T, Nakamura Y, Ishigaki Y, Shimodaira S. Quality Verification with a Cluster-Controlled Manufacturing System to Generate Monocyte-Derived Dendritic Cells. Vaccines (Basel). 2021 May 20;9(5):533. doi: 10.3390/vaccines9050533.
  5. Watanabe A, Togi M, Koya T, Taniguchi M, Sakamoto T, Iwabuchi K, Kato T Jr, Shimodaira S. Identification of CD56dim subpopulation marked with high expression of GZMB/PRF1/PI-9 in CD56+ interferon-α-induced dendritic cells. Genes Cells. 2021 May;26(5):313-327. doi: 10.1111/gtc.12844. Epub 2021 Mar 29.
  6. Date I, Koya T, Sakamoto T, Togi M, Kawaguchi H, Watanabe A, Kato T Jr, Shimodaira S. Interferon-α-Induced Dendritic Cells Generated with Human Platelet Lysate Exhibit Elevated Antigen Presenting Ability to Cytotoxic T Lymphocytes. Vaccines (Basel). 2020 Dec 24;9(1):E10. doi: 10.3390/vaccines9010010.
  7. Kan S, Bito T, Shimabuku M, Taguchi J, Ohkusa T, Shimodaira S, Sugiyama H, Koido S. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells. Int J Oncol. 57(4):1047-1056, 2020. doi: 10.3892/ijo.2020.5110.
  8. Koya T, Date I, Kawaguchi H, Watanabe A, Sakamoto T, Togi M, Kato T Jr, Yoshida K, Kojima S, Yanagisawa R, Koido S, Sugiyama H, Shimodaira S. Dendritic Cells Pre-Pulsed with Wilms’ Tumor 1 in Optimized Culture for Cancer Vaccination. Pharmaceutics. 12(4):305, 2020. doi: 10.3390/pharmaceutics12040305.
  9. Shimodaira S, Yanagisawa R, Koya T, Hirabayashi K, Higuchi Y, Sakamoto S, Togi M, Kato T Jr, Kobayashi T, Koizumi T, Koido S, and Sugiyama H. In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination. Vaccines 7(3), 120, 2019. doi:10.3390/vaccines7030120.
  10. Ito Z, Kan S, Bito T, Horiuchi S, Akasu T, Kajihara M, Yoshida S, Hokari A, Masayuki, Saruta M, Yoshida N, Kobayashi M, Ohkusa T, Shimodaira S, Okamoto M, Sugiyama H, Koido S. Predicted markers of overall survival in pancreatic cancer patients receiving dendritic cell vaccines targeting WT1. Oncology 97(3):135-148, 2019. doi: 10.1159/000500359.
  11. Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Saruta M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Shimodaira S, Okamoto M, Sugiyama H, Koido S. Prognostic significance of Wilms’ tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Oncol Lett 16(2): 2682-2692, 2018. doi: 10.3892/ol.2018.8961.
  12. Hirabayashi K, Yanagisawa R, Saito S, Higuchi Y, Koya T, Sano K, Koido S, Okamoto M, Sugiyama H, Nakazawa Y, Shimodaira S. Feasibility and immune response of WT1 peptide vaccination in combination with OK-432 for paediatric solid tumors. Anticancer Res 38(4): 2227-2234, 2018.
  13. Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H, Shimodaira S. WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study. Anticancer Res 38(4): 2217-2225, 2018.
  14. Koido S, Okamoto M, Kobayashi M, Shimodaira S, Sugiyama H. Significance of Wilms’ tumor 1 antigen as a cancer vaccine for pancreatic cancer. Discov Med. 24(130):41-49, 2017.
  15. Koya T, Yanagisawa R, Higuchi Y, Sano K, Shimodaira S. Interferon-ɑ-inducible dendritic cells matured with OK-432 exhibit TRAIL and Fas ligand pathway-mediated killer activity. Sci Rep. 7:42145. 2017. doi: 10.1038/srep42145.

その他

  1. 第7節アカデミアにおけるGMPに対応した細胞培養及び保管システムの構築
    バイオロジカルクリーンルームの設計・維持管理と作業員教育
    下平滋隆，小屋照継，石垣靖人
    技術情報協会　2018年2月
  2. 研究および試験用の脂肪組織由来幹細胞（ADSC）バンクの構築
    石垣靖人，中村有香，小屋照継，加藤友久，下平滋隆
    PHARM STAGE Vol.18,No.10,2019

成果発表等